2-甲氧基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯 | 1146214-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲氧基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯
• 中文别名: 3-甲氧基-2-(甲氧基羰基)苯基硼酸,频哪醇酯
• 英文名称: methyl 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
• CAS: 1146214-77-8
• 化学式: C₁₅H₂₁BO₅
• 分子量: 292.14
• InChiKey: RAGDNDSTZKPURP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.78
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

SDS

MSDS英文版

反应信息

• 作为反应物：
  描述：

  2-甲氧基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯 在 copper(l) iodide 、 1,10-菲罗啉 、 potassium iodide 作用下， 以 甲醇 、 水 为溶剂， 反应 10.0h， 以60%的产率得到methyl 2-iodo-6-methoxybenzoate
  参考文献：
  名称：

  N,B-Bidentate Boryl Ligand-Supported Iridium Catalyst for Efficient Functional-Group-Directed C–H Borylation

  摘要：

  Convenient silylborane precursors for introducing N,B-bidentate boryl ligands onto transition metals were designed, prepared, and employed in ready formation of irdium(III) complexes via Si-B oxidative addition. A practical, efficient catalytic ortho-borylation reaction of arenes with a broad range of directing groups was developed using an in situ generated catalyst from the silylborane preligand 3c and [IrCl(COD)](2).

  DOI：

  10.1021/jacs.6b11867
• 作为产物：
  描述：

  2-溴-6-甲氧基苯甲酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醚 、 甲苯 为溶剂， 反应 16.5h， 生成 2-甲氧基-6-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯
  参考文献：
  名称：

  硒催化的C（sp3）？H酰氧基化：在异苯并呋喃酮的简便合成中的应用

  摘要：

  氧化的Se催化的C（sp 3）H键酰氧基化已被用来从简单的邻烯丙基苯甲酸衍生物构造出各种各样的异苯并呋喃酮。合成过程采用温和的反应条件，并通过廉价的有机二硒烷催化剂实现了高化学选择性。提出的方法为邻苯二甲酰亚胺天然产物的核心结构提供了一条新的合成途径。

  DOI：

  10.1002/chem.201406290

文献信息

• SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：COATE Heather R.

  公开号：US20160046640A1

  公开（公告）日：2016-02-18

  The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; R 1 is H, alky], aikoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; R 2 is H, alkyl, aikoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R 5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中环A为苯基、萘基、吡啶基、喹啉基、异喹啉基、咪唑吡啉基、呋喃基、噻唑基、异噁唑基、吡唑基、咪唑噻唑基、苯并咪唑基或吲哚基；R1为H、烷基、烷氧基、羟基烷基、OH、卤素、苯基、三唑基、噁唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、哌嗪基、吡唑基、噁二唑基、吡咯烷基、噻吩基、吗啉基或二烷氨基；R2为H、烷基、烷氧基、羟基烷基或卤素；Z为NH、N-烷基或O；R5为吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、喹唑啉基、喹喹啉基、吡唑基、苯并噁唑基、咪唑吡嗪基、三唑咪唑基，可选地取代一个或两个独立选择自烷基、烷氧基或卤素的基团；n为0或1，还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的药物组合物。本发明还涉及使用该化合物的方法。
• Synthesis of Thioxanthones through Formal C–H Thiolation of Benzoic Acid Esters and Acid-mediated Direct Cyclization
  作者：Kotaro Mutsuura、Yuki Sakata、Keisuke Uchida、Takamitsu Hosoya、Suguru Yoshida

  DOI：10.1246/cl.200190

  日期：2020.7.5

  An efficient thioxanthone synthesis from benzoic acid esters is disclosed. Various thioxanthones were prepared by iridium-catalyzed C–H borylation of benzoic acid esters followed by copper-catalyze...

  公开了一种由苯甲酸酯有效合成噻吨酮。各种噻吨酮是通过铱催化苯甲酸酯的 C-H 硼酸化和铜催化制备的。
• [EN] OREXIN 1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE 1
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2020120994A1

  公开（公告）日：2020-06-18

  The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

  本公开涉及公式（I）的新化合物及其盐，其中W；X；Y；Z；R1；R2；R3和R4在此处定义，并其在治疗、预防、改善、控制或减少与促进素受体相关的神经系统或精神障碍的风险中的用途。
• Substituted 7-azabicyles and their use as orexin receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US09062078B2

  公开（公告）日：2015-06-23

  The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphthalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyl, thiazolyl, isoxazolyl, pyrazolyl, imidazothiazolyl, benzimidazolyl, or indazolyl; R1 is H, alkyl, alkoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, thiophenyl, morpholinyl, or dialkylamino; R2 is H, alkyl, alkoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinazolinyl, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, alkoxy, or halo; and n is 0 or 1. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中环A是苯基，萘基，吡啶基，喹啉基，异喹啉基，咪唑吡啶基，呋喃基，噻唑基，异恶唑基，吡唑基，咪唑噻唑基，苯并咪唑基或吲唑基; R1是H，烷基，烷氧基，羟基烷基，OH，卤素，苯基，三唑基，噁唑基，异噁唑基，吡啶基，嘧啶基，吡嗪基，吡啶并嗪基，哌嗪基，吡唑基，噁二唑基，吡咯烷基，噻吩基，吗啉基或二烷基氨基; R2是H，烷基，烷氧基，羟基烷基或卤素; Z是NH，N-烷基或O; R5是吡啶基，嘧啶基，吡嗪基，吡啶并嗪基，喹唑啉基，喹喔啉基，吡唑基，苯并噁唑基，咪唑吡嗪基，三唑基咪唑基，可选地带有一个或两个烷基，烷氧基或卤素基团; n为0或1。还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的制药组合物。使用本发明中的化合物的方法也属于本发明的范围。
• Substituted 2-azabicycles and their use as orexin receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US08969352B2

  公开（公告）日：2015-03-03

  The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中X为N或CR1; Y为N或CR2; R1为H、烷氧基、卤素、三唑基、嘧啶基、噁唑基、异噁唑基、噻二唑基或吡唑基; R2为H、烷基、烷氧基或卤素; Z为NH或O; R3为H、烷基、烷氧基、卤素或三唑基; R4为H或烷基; 或R3和R4与它们附着的原子一起形成6元芳基环或5-或6元杂芳基环; R5为吡啶基、吡嗪基或嘧啶基，其中吡啶基、吡嗪基或嘧啶基可以选择性地用卤素或烷基取代; n为1或2。还描述了制备式I化合物的方法。本发明还涉及包括式I化合物的制药组合物。使用本发明化合物的方法也在本发明的范围内。